Leadiant Biosciences, Inc. announced it is conducting the Registry Study of Revcovi® (elapegademase-lvlr) injection 1.6 mg/ml Treatment in Patients with Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID).
Read More
Leadiant Biosciences, Inc. announced it is conducting the Registry Study of Revcovi® (elapegademase-lvlr) injection 1.6 mg/ml Treatment in Patients with Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID).